Iron Replacement as A Therapeutic Approach For Renal Phosphate Wasting With Associated Iron Deficiency

ABSTRACT: Objective: Fibroblast growth factor 23 (FGF23) dysregulation is implicated in the pathogenesis of hypophosphatemic disorders, including X-linked hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets, and tumor-induced ost...

Full description

Bibliographic Details
Main Authors: Aditi Kumar, MD, Robert A. Wermers, MD, Peter J. Tebben, MD
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:AACE Clinical Case Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2376060520301723
id doaj-aded8a2590a74ba4a6627ca6bb1a2418
record_format Article
spelling doaj-aded8a2590a74ba4a6627ca6bb1a24182021-04-30T07:23:48ZengElsevierAACE Clinical Case Reports2376-06052017-01-0133e260e263Iron Replacement as A Therapeutic Approach For Renal Phosphate Wasting With Associated Iron DeficiencyAditi Kumar, MD0Robert A. Wermers, MD1Peter J. Tebben, MD2From the 1Division of Endocrinology, Diabetes, Metabolism and Nutrition and Department of Medicine, Mayo Clinic, Rochester, Minnesota.From the 1Division of Endocrinology, Diabetes, Metabolism and Nutrition and Department of Medicine, Mayo Clinic, Rochester, Minnesota.From the 1Division of Endocrinology, Diabetes, Metabolism and Nutrition and Department of Medicine, Mayo Clinic, Rochester, Minnesota.; Division of Pediatric Endocrinology and Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.; Address correspondence to Dr. Peter Tebben, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.ABSTRACT: Objective: Fibroblast growth factor 23 (FGF23) dysregulation is implicated in the pathogenesis of hypophosphatemic disorders, including X-linked hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets, and tumor-induced osteomalacia (TIO). Studies have suggested a role of iron deficiency in triggering FGF23 dysregulation in ADHR.Methods: We report a case of adult-onset FGF23-mediated hypophosphatemic osteomalacia with associated iron deficiency that had significant clinical improvement and reduction in FGF23 with iron replacement.Results: A 41-year-old female presented with progressively worsening muscle weakness and diffuse pain for 4 years, resulting in wheelchair dependence. She had hypophosphatemia, renal phosphate wasting, and an elevated FGF23. Extensive imaging for TIO was nonlocalizing. Family history was negative for bone disease. Despite phosphorus and calcitriol therapy, her phosphorus remained low and she had progressive weakness. She was noted to have iron deficiency, and initiation of iron replacement resulted in progressive clinical improvement, such that she was capable of ambulating for short distances unassisted after 6 months of iron replacement. Hypophosphatemia improved and FGF23 almost normalized after 50 weeks of iron therapy. Sequencing of the FGF23 gene was negative.Conclusion: Our case suggests that in addition to ADHR, iron deficiency may play a role in the pathophysiology of other FGF23-mediated disorders of renal phosphate wasting. Iron replacement may be a potential treatment option for such patients. Further studies will be needed to confirm this clinical observation.Abbreviations:ADHR = autosomal dominant hypophosphatemic ricketsFePi = fractional excretion of phosphorusFGF23= fibroblast growth factor 23http://www.sciencedirect.com/science/article/pii/S2376060520301723
collection DOAJ
language English
format Article
sources DOAJ
author Aditi Kumar, MD
Robert A. Wermers, MD
Peter J. Tebben, MD
spellingShingle Aditi Kumar, MD
Robert A. Wermers, MD
Peter J. Tebben, MD
Iron Replacement as A Therapeutic Approach For Renal Phosphate Wasting With Associated Iron Deficiency
AACE Clinical Case Reports
author_facet Aditi Kumar, MD
Robert A. Wermers, MD
Peter J. Tebben, MD
author_sort Aditi Kumar, MD
title Iron Replacement as A Therapeutic Approach For Renal Phosphate Wasting With Associated Iron Deficiency
title_short Iron Replacement as A Therapeutic Approach For Renal Phosphate Wasting With Associated Iron Deficiency
title_full Iron Replacement as A Therapeutic Approach For Renal Phosphate Wasting With Associated Iron Deficiency
title_fullStr Iron Replacement as A Therapeutic Approach For Renal Phosphate Wasting With Associated Iron Deficiency
title_full_unstemmed Iron Replacement as A Therapeutic Approach For Renal Phosphate Wasting With Associated Iron Deficiency
title_sort iron replacement as a therapeutic approach for renal phosphate wasting with associated iron deficiency
publisher Elsevier
series AACE Clinical Case Reports
issn 2376-0605
publishDate 2017-01-01
description ABSTRACT: Objective: Fibroblast growth factor 23 (FGF23) dysregulation is implicated in the pathogenesis of hypophosphatemic disorders, including X-linked hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets, and tumor-induced osteomalacia (TIO). Studies have suggested a role of iron deficiency in triggering FGF23 dysregulation in ADHR.Methods: We report a case of adult-onset FGF23-mediated hypophosphatemic osteomalacia with associated iron deficiency that had significant clinical improvement and reduction in FGF23 with iron replacement.Results: A 41-year-old female presented with progressively worsening muscle weakness and diffuse pain for 4 years, resulting in wheelchair dependence. She had hypophosphatemia, renal phosphate wasting, and an elevated FGF23. Extensive imaging for TIO was nonlocalizing. Family history was negative for bone disease. Despite phosphorus and calcitriol therapy, her phosphorus remained low and she had progressive weakness. She was noted to have iron deficiency, and initiation of iron replacement resulted in progressive clinical improvement, such that she was capable of ambulating for short distances unassisted after 6 months of iron replacement. Hypophosphatemia improved and FGF23 almost normalized after 50 weeks of iron therapy. Sequencing of the FGF23 gene was negative.Conclusion: Our case suggests that in addition to ADHR, iron deficiency may play a role in the pathophysiology of other FGF23-mediated disorders of renal phosphate wasting. Iron replacement may be a potential treatment option for such patients. Further studies will be needed to confirm this clinical observation.Abbreviations:ADHR = autosomal dominant hypophosphatemic ricketsFePi = fractional excretion of phosphorusFGF23= fibroblast growth factor 23
url http://www.sciencedirect.com/science/article/pii/S2376060520301723
work_keys_str_mv AT aditikumarmd ironreplacementasatherapeuticapproachforrenalphosphatewastingwithassociatedirondeficiency
AT robertawermersmd ironreplacementasatherapeuticapproachforrenalphosphatewastingwithassociatedirondeficiency
AT peterjtebbenmd ironreplacementasatherapeuticapproachforrenalphosphatewastingwithassociatedirondeficiency
_version_ 1721498509302038528